Company / Operating Income
Cartesian Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$43.9M
FY2025
5-year range
-$86.4M / -$4.6M
FY2021-FY2025
Trend
+49.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 8 years, ranging from -$86M in FY2024 to -$5M in FY2023.
Based on SEC 10-K filings.
-$44M in FY2025.
Declined from -$5M to -$44M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 49.2% year-over-year.
- Peak operating income was recorded in FY2023.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$43.9M | +49.2% |
| FY2024 | -$86.4M | -1779.8% |
| FY2023 | -$4.6M | +91.9% |
| FY2022 | -$56.8M | -8.3% |
| FY2021 | -$52.5M | +19.3% |
| FY2020 | -$65.0M | -1.9% |
| FY2019 | -$63.8M | -314.2% |
| FY2016 | -$15.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026